Non-overt disseminated intravascular coagulation scoring for critically ill patients: The impact of antithrombin levels

Summary

Validation of a scoring algorithm for non-overt disseminated intravascular coagulation (DIC) proposed by the International Society on Thrombosis and Haemostasis (ISTH) is still incomplete. It was the objective of this study to assess the impact of including AT to non-overt DIC scoring on the predictability for intensive care unit (ICU) death and the later development of overt-DIC defined by the Japanese Ministry of Health and Welfare (JMHW) or the ISTH. We performed a retrospective observational study conducted in 364 patients in critical care. Coagulation parameters obtained daily for DIC screening were utilised for scoring. There were 194 and 196 patients scored as positive non-overt DIC with and without AT, respectively; diagnostic agreement between the two was 78%. As compared with patients without non-overt DIC, these non-overt DIC patients had significantly higher mortality. In 37 ICU non-survivors, positive non-overt DIC scoring with AT preceded ICU death by a median of 6.8 days, which was significantly earlier as compared with a median of 5.4 days for non-overt DIC without AT (p=0.022). In patients who developed overt-DIC after admission, the time period from positive non-overt DIC to positive overt-DIC was significantly longer when AT was utilised (overt-DIC ISTH; 1.3 days vs. 0.1 days, p=0.004, overt-DIC JMHW; 2.5 days vs. 2.0 days, p=0.04, with AT vs. without AT, respectively). Non-overt DIC scoring predicted a high risk of death in critically ill patients. When information on AT levels was included, non-overt DIC scoring was found to predict development of overt-DIC significantly earlier than non-overt DIC scoring without AT.

Keywords

Disseminated intravascular coagulation - antithrombin - predictability - International Society on Thrombosis and Haemostasis - validation

• References

• 1 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
• 2 Muller-Berghaus G, ten Cate H, Levi M. Disseminated intravascular coagulation: clinical spectrum and established as well as new diagnostic approaches. Thromb Haemost 1999; 82: 706-712.
• 3 ten Cate H, Timmerman JJ, Levi M. The patho-physiology of disseminated intravascular coagulation. Thromb Haemost 1999; 82: 713-717.
• 4 Levi M, de Jonge E, van der Poll T. et al. Disseminated intravascular coagulation. Thromb Haemost 1999; 82: 695-705.
• 5 Taylor Jr FB, Toh CH, Hoots WK. et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-1330.
• 6 Wada H, Gabazza EC, Asakura H. et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society on Thrombosis and Haemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol 2003; 74: 17-22.
• 7 Bernard GR, Vincent JL, Laterre PF. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
• 8 Warren BL, Eid A, Singer P. et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J Am Med Assoc 2001; 286: 1869-1878.
• 9 Hoffmann JN, Wiedermann CJ, Juers M. et al. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006; 95: 850-856.
• 10 Wiedermann CJ, Hoffmann JN, Juers M. et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006; 34: 285-292.
• 11 Afshari A, Wetterslev J, Brok J. et al. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Br Med J 2007; 335: 1248-1251.
• 12 Saito H, Maruyama I, Shimazaki S. et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5: 31-41.
• 13 Toh CH, Downey C. Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2005; 16: 69-74.
• 14 Toh CH, Hoots WK. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost 2007; 5: 604-606.
• 15 Knaus WA, Draper EA, Wagner DP. et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
• 16 National Association of Testing Authorities. Available from: http://www.nata.asn.au
• 17 Hayakawa M, Gando S, Hoshino H. A prospective comparative study of three sets of criteria for disseminated intravascular coagulation: ISTH criteria vs Japanese criteria. Clin Appl Thromb Hemost 2007; 13: 65-72.
• 18 Hayakawa M, Gando S, Hoshino H. A Prospective comparison of new Japanese criteria for disseminated intravascular coagulation: new Japanese criteria versus ISTH criteria. Clin Appl Thromb Hemost 2007; 13: 172-181.
• 19 Kienast J, Juers M, Wiedermann CJ. et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4: 90-97.
• 20 Sakr Y, Reinhart K, Hagel S. et al. Antithrombin levels, morbidity, and mortality in a surgical intensive care unit. Anesth Analg 2007; 105: 715-723.
• 21 Ranucci M, Frigiola A, Menicanti L. et al. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005; 33: 355-360.
• 22 Mesters RM, Mannucci PM, Coppola R. et al. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996; 88: 881-886.
• 23 Aibiki M, Fukuoka N, Nishiyama T. et al. Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: a pharmacokinetic study. Shock 2007; 28: 141-147.
• 24 Asakura H, Ontachi Y, Mizutani T. et al. Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Eur J Haematol 2001; 67: 170-175.
• 25 Rodeghiero F, Mannucci PM, Vigano S. et al. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood 1984; 63: 965-969.
• 26 American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
• 27 Gando S, Iba T, Eguchi Y. et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006; 34: 625-631.
• 28 Gando S, Wada H, Asakura H. et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Hemost 2005; 11: 71-76.
• 29 Le Gall JR, Klar J, Lemeshow S. et al. The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. J Am Med ASsoc 1996; 276: 802-810.
• 30 Angstwurm MW, Dempfle CE, Spannagl M. New disseminated intravascular coagulation score: A useful tool to predict mortality in comparison with Acute Physiology and Chronic Health Evaluation II and Logistic Organ Dysfunction scores. Crit Care Med 2006; 34: 314-320.